Which is better, BPC-157 or GHK-Cu?
GHK-Cu is graded human observational because controlled cosmetic studies of topical creams report improved skin firmness, elasticity, and wrinkles, and topical products are lawful to buy. BPC-157 is graded animal only, with no controlled human trial, and it has no lawful compounded path until FDA publishes a final rule. The edge applies to topical skin use; for tendon or gut problems neither has human evidence, and the GHK-Cu human data are small studies summarized mostly by the peptide's discoverer. [2] [6] [7] [8] [10]
How do BPC-157 and GHK-Cu compare?
| Dimension | BPC-157 | GHK-CuFavored |
|---|---|---|
| What it is [4] [7] | Synthetic 15 amino acid fragment of a gastric protein (body protection compound). | Naturally occurring tripeptide (glycyl-histidyl-lysine) bound to copper, found in human plasma, saliva, and urine. |
| Evidence grade [2] [6] [12] | Animal only. No controlled human trial; human data limited to three small uncontrolled pilot reports from one clinic. | Human observational for topical skin use: small controlled cosmetic studies, cited through reviews. No human trial of injected GHK-Cu. |
| Main use case in the literature [1] [4] [5] [6] | Tendon, ligament, muscle, and gastrointestinal healing in rodents, including NSAID induced ulcers and fistulas. | Skin aging and photodamage in humans (topical), plus wound, hair follicle, and bone healing in rodents, pigs, and dogs. |
| Proposed mechanism [3] [5] [7] | Growth factor receptor upregulation, nitric oxide system modulation, and VEGFR2 driven angiogenesis in animal and cell models. | Delivers copper to cells, attracts repair cells, increases collagen, elastin, and glycosaminoglycan synthesis, and dampens NF-kB and TNF-alpha signaling in cell and animal models. |
| Routes with data [4] [6] | Injection, oral in drinking water, and topical in rodents. No human route has published data. | Topical cream or serum in humans (the only form with human data). Injection has no human data. |
| FDA and compounding status [8] [9] [10] | Removed from 503A Category 2 on April 15, 2026; PCAC recommended adding it to the 503A bulks list in July 2026; no final rule yet. Not FDA approved. | Topical: lawful cosmetic ingredient if no drug claims are made. Injectable: nomination withdrawn, so it is no longer in Category 2 but is not on the bulks list and was not reviewed by PCAC. Not FDA approved as a drug. |
| Access without a prescription [8] [10] | None lawful. Research chemical products are not lawful for human use. | Topical cosmetic products are sold over the counter. Injectable GHK-Cu has no lawful compounded path: it is off Category 2 but not on the 503A bulks list. |
| WADA status [11] | Prohibited at all times under S0 (non-approved substances). | Not named on the list. Topical cosmetic use is not a recognized concern, but injected GHK-Cu may fall under S0 as a non-approved substance, so status is unclear. |
| Typical cost [8] [10] | No lawful compounded price: not on the 503A bulks list, and advertised clinic prices are not a comparable price. | Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. No lawful compounded price for injectable GHK-Cu, which is not on the 503A bulks list. |
Evidence grade and regulatory status
Pulled from each peptide’s own record, so it stays in step with the peptide pages.
| Attribute | BPC-157 | GHK-Cu |
|---|---|---|
| Class | Synthetic gastric pentadecapeptide (15 amino acids), fragment of body protection compound | Naturally occurring tripeptide (glycyl-histidyl-lysine) complexed with copper(II); found in human plasma, saliva, and urine |
| What it is | A 15 amino acid peptide with strong animal healing data, no randomized human trial in PubMed, and a shifting FDA compounding status. | Copper binding three amino acid peptide with decades of skin and wound data: lawful and well studied in skin cosmetics, unapproved and untested as an injection. |
| Evidence | Evidence: Animal-only evidence | Evidence: Human observational evidence |
| FDA status | Regulatory: Under FDA review | Regulatory: Removed from Category 2 (Apr 2026) |
| Compounding | Removed from the FDA 503A Category 2 list (substances with significant safety risks) on April 15, 2026. On July 23 to 24, 2026 the Pharmacy Compounding Advisory Committee recommended adding BPC-157 to the 503A bulks list. As of the last verification date FDA has not published a final rule listing it, so state boards and pharmacies vary in whether they will compound it. It is not an FDA approved drug and is not eligible for 503B outsourcing. | GHK-Cu has two regulatory tracks. As a cosmetic ingredient in topical products it is lawfully marketed without FDA premarket approval, provided no drug claims are made. As an injectable drug it is not FDA approved and is not a component of any approved drug. GHK-Cu for injectable routes was nominated for the 503A bulks list and placed in 503A Category 2; the FDA Category 2 page current as of April 22, 2026 now lists it under bulk drug substances nominated but withdrawn, so it is no longer in Category 2 but is not on the bulks list and was not reviewed by the Pharmacy Compounding Advisory Committee in July 2026. Because it is not on the bulks list, a 503A pharmacy has no federal basis to compound injectable GHK-Cu from bulk, and state boards cannot authorize what federal law does not. Injectable products sold as research chemicals are not lawful for human use. |
| WADA | WADA: WADA prohibited | WADA: WADA status unclear |
| Routes | Subcutaneous injection (as sold), Oral capsule (as sold), Intraperitoneal, oral in water, and topical (animal studies) | Topical cream or serum (cosmetic use, the only form with human data), Subcutaneous injection (as sold; no human data), Topical, intraperitoneal, and systemic (animal studies) |
| Typical cost | No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Last verified |
Has BPC-157 been tested directly against GHK-Cu?
No published trial has compared BPC-157 and GHK-Cu directly. The dimensions above come from separate studies and labels, and cross-trial comparisons are less reliable than a direct trial.
What do BPC-157 and GHK-Cu cost?
| Dimension | BPC-157 | GHK-Cu |
|---|---|---|
| Typical cost | No lawful compounded price: BPC-157 is not on the 503A bulks list, and PCAC's July 2026 recommendation is advisory until FDA publishes a final rule. Advertised clinic prices are not a comparable price. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. | Topical cosmetic serums and creams roughly 20 to 100 USD per bottle. There is no lawful compounded price for injectable GHK-Cu: it is off 503A Category 2 but is not on the 503A bulks list and was not recommended by PCAC in July 2026. Products sold as research chemicals are not lawful for human use and are not verified for identity or purity. |
| Price detail | BPC-157 price by channel | GHK-Cu price by channel |
Where a price index exists, the range is the cash price per month across branded, compounded, and telehealth channels, without insurance. The cost pages give each channel separately with its sources. Otherwise the typical cost from the peptide record is shown. Legal access depends on your state: see peptide legality by state.
Are BPC-157 and GHK-Cu combined?
BPC-157 and GHK-Cu are sold together in the premixed blends below. No study has tested the combination, and a mix is only as lawful as its least lawful ingredient. The blend pages cover what is in each product, the evidence for each ingredient, and legal status.
Frequently asked questions
Which is better for skin, BPC-157 or GHK-Cu?
GHK-Cu. Small controlled cosmetic studies of topical GHK-Cu creams report tighter skin, better elasticity and density, and fewer fine lines, and those products are sold over the counter. BPC-157 has no human skin data. [6] [7] [10]
Which is better for tendon or joint injuries?
Neither has human evidence for tendon or joint injuries. BPC-157 has rodent tendon studies showing faster Achilles healing; GHK-Cu animal data focus on skin, hair follicle, and bone healing. Standard care remains physical therapy and load management. [1] [2] [5]
Is injectable GHK-Cu better studied than injectable BPC-157?
No. Neither has a controlled human trial of injection. BPC-157 has three small uncontrolled pilot reports from one clinic, and GHK-Cu's human data come only from topical cosmetic products, which tell you nothing about injected doses or safety. [6] [12]
Can I get either one legally?
Only topical GHK-Cu, which is sold as a cosmetic ingredient in creams and serums as long as no drug claims are made. Neither BPC-157 nor injectable GHK-Cu has a lawful compounded path today: BPC-157 awaits an FDA final rule after the July 2026 advisory committee vote, and injectable GHK-Cu is off Category 2 but not on the 503A bulks list. Research chemical vials are not lawful for human use. [8] [9] [10]
Do both carry a cancer concern?
Both have a theoretical concern because they promote angiogenesis or cell proliferation in animal and cell models, though neither has been shown to promote tumors in humans. Reviews of GHK also report anti-cancer activity in vitro, so the question is unresolved. [3] [5]
Conditions studied
- Tendon injury and tendinopathy
- Muscle recovery and injury
- Skin aging and cosmetic repair
- Wound healing
- Inflammation and inflammatory bowel disease
- Inflammatory bowel disease (Crohn disease and ulcerative colitis)
- Irritable bowel syndrome
- Hair loss (androgenetic alopecia)
- Traumatic brain injury
- Osteoarthritis
- Chronic pain
From the blog
- Copper peptides for hair: what the studies show
Does GHK-Cu help with hair growth? Copper peptides enlarge hair follicles in lab and mouse studies, but no randomized trial of GHK-Cu alone for hair loss exists. How they compare with minoxidil.
- Klow vs Glow peptide: what KPV adds and what is known
Klow is the Glow blend (GHK-Cu, BPC-157, TB-500) plus KPV. Each ingredient compared, what KPV is claimed to add, how both relate to the Wolverine stack, and why no study tests either blend.
- Topical vs injectable GHK-Cu: what the evidence shows
Topical GHK-Cu has small skin studies and is a lawful cosmetic. Injectable GHK-Cu has no human trial and no lawful compounding path. Evidence, absorption, safety, and legality compared.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (J Appl Physiol 2011)PubMed 21030672, 2011
- [2]Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Cell Tissue Res 2019)PubMed 30915550, 2019
- [3]Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications (Curr Neuropharmacol 2016)PubMed 27138887, 2016
- [4]Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Curr Pharm Des 2011)PubMed 21548867, 2011
- [5]Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. Int J Mol Sci 2018PubMed 29986520, 2018
- [6]Pickart L, Vasquez-Soltero JM, Margolina A. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration. Biomed Res Int 2015PubMed 26236730, 2015
- [7]Pickart L. The human tri-peptide GHK and tissue remodeling. J Biomater Sci Polym Ed 2008PubMed 18644225, 2008
- [8]FDA: Bulk drug substances used in compounding under section 503A of the FD&C Act (links to the Category 1, 2, and 3 lists and the bulks list)FDA, 2026
- [9]FDA Pharmacy Compounding Advisory Committee meetings (July 2026 meeting on peptide nominations)FDA, 2026
- [10]FDA: Is it a cosmetic, a drug, or both? (or is it soap?)FDA, 2024
- [11]WADA Prohibited List, section S0 non-approved substancesWADA, 2026
- [12]McGuire FP et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Curr Rev Musculoskelet Med 2025PubMed 40789979, 2025
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 23). BPC-157 vs GHK-Cu: evidence, cost, and legality. https://peptideagent.ai/compare/bpc-157-vs-ghk-cu- HTML link
<a href="https://peptideagent.ai/compare/bpc-157-vs-ghk-cu">BPC-157 vs GHK-Cu: evidence, cost, and legality</a>, PeptideAgent, updated September 23, 2026.